Publications
460
Citations
6,363
Est. group size
~96
Recurring co-author estimate
Active years
15
Publishing since 2012
James S. Blachly's research focuses on blood cancers, particularly leukemias such as acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). Recent work centers on a clinical trial testing a CAR T-cell therapy (an engineered immune-cell treatment) targeting the CLL-1 protein for patients with relapsed or treatment-resistant AML. This research falls within clinical and translational hematology-oncology, with an emphasis on developing and evaluating new cellular immunotherapies for leukemia.
Publication output has grown substantially over the last decade, rising from about 15 papers per year in 2017-2018 to a much higher and variable pace (including a spike to 118 in 2023 and 73 in 2026), indicating an overall increasing and currently high level of activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Supplemental Table 9 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Table 8 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Figure 3 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Table 6 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Methods1 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Table 6 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Table 2 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Figure 4 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Table 2 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Table 4 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Figure 3 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Table 9 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Table 5 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Table 7 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Supplemental Figure 2 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2026
- Blood×113
- Leukemia×20
- Journal of Clinical Oncology×10
- Blood Advances×10
- Clinical Lymphoma Myeloma & Leukemia×10
- Daniel Jones
Medicine · The Ohio State University
- Mitch A. Phelps
Medicine · The Ohio State University
- Dan Jones
Medicine · The Ohio State University
- Charles T. Gregory
Medicine · The Ohio State University
- Amy S. Ruppert
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile